ESPE Abstracts (2022) 95 P1-482

ESPE2022 Poster Category 1 Fat, Metabolism and Obesity (73 abstracts)

Liraglutide SC in the treatment of severe obesity in Pediatrics: a missed therapeutic opportunity?

Ignacio Diez-Lopez 1,2 , Ainhoa Sarasua-Miranda 1 & Mari Jose Espina-Diez 1

5 views


1OSI Araba. Peadiatric Service, Vitoria, Spain; 2Pediatric Departament, Basque Country University, UPV-EHU, Vitoria, Spain


Liraglutide 3.0 mg has been shown to improve body mass index (BMI) and weight in obese adolescents. And it has done so in a randomized, double-blind, phase 3 clinical trial that has investigated the effect of liraglutide 3mg. compared with placebo for weight control in 251 obese minors, and as a complement to a healthy lifestyle. Adverse events associated with the use of liraglutide 3.0 in pediatric patients are not very different from those observed in adults. There may be cases of gastrointestinal discomfort such as a feeling of excessive gastric fullness, nausea on occasion and, more rarely, vomiting, all especially during the first weeks of administration. Liraglutide 3.0 mg, although it requires a prescription for sale, is not funded by the SPS. Cost of a box of 5 pens is €283.05 The progressive increase in the prevalence of overweight and obesity in this age group. At Spain it can reach up to 40%. These have led to the appearance of new family models, eating habits and life models that facilitate the development of obesity in new generations. There are social and ethnic groups where the prevalence of childhood obesity is more prevalent.

Objective: To evaluate the clinical experience in the incorporation of SAXENDA in routine clinical practice.

Methods: severely obese patients over 12 years of age who are likely to use liraglutide under the indication of the technical data sheet. Presentation of the product and offer to the family. Socio-economic study in direct interview, sex, age. Collection of impressions, in case of refusal the cause.

Results: 45 children older than 12 years (15♂), mean age 13.5 to [12-16]. Mean follow-up time in SCC of 3.5 years [2.8-5.2]. HbA1c (DCA): 5.7% [5-6.2], no DM 2, mean BMI 35.28 kg/m2 [29,42]. Ethnic origin 90% foreigners. Socioeconomic level manifested low (20/45), medium-low (12/45), medium (12/45), high (1/45), very high (0/45). Rejection 40/45, value next visit 4/45, acceptance 1/45 Reasons for rejection: fear of needles 25/40, price 30/40, distrust 3/40, others 2/40.

Conclusion: We assume that this study may present some deficiencies due to the size of the sample, but our study demonstrates the possibility of the limitation of a therapeutic tool associated with price, delving deeper into the poverty-disease-poverty circle. We believe that this drug should be financed even if its prescription in pediatrics is regulated or inspected.

Volume 95

60th Annual ESPE (ESPE 2022)

Rome, Italy
15 Sep 2022 - 17 Sep 2022

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.

Authors